Ruxolitinib (Jakafi)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Myelofibrosis, Polycythemia Vera, Graft-versus-Host Disease, Chronic Graft-versus-Host Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
JP
  • Treatment of myelofibrosis
Product first approved 2014PMDA
EU
  • Disease-related splenomegaly or symptoms in adults with primary myelofibrosis (Jakavi; also polycythaemia vera and GvHD)
Product first approved 2012EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (27)
Graft-versus-Host Disease
NCT04769895 · MaaT Pharma
2022-03-25 – 2025-11 · Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD
What this study did
Myelofibrosis
NCT02598297 · Novartis Pharmaceuticals
2016-02-03 – 2017-10-23 · Myelofibrosis With High Molecular Risk Mutations
What this study did
NCT01493414 · Novartis Pharmaceuticals
2011-08-16 – 2017-01-26 · Myelofibrosis
What this study did
Polycythemia Vera
NCT04116502 · University of Birmingham
2019-10-25 – 2030-04-01 · Polycythemia Vera
What this study did
NCT03755518 · Celgene
2019-03-27 – 2023-11-08 · Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
What this study did
NCT02038036 · Novartis Pharmaceuticals
2014-03-25 – 2020-04-07 · Polycythemia Vera
What this study did
NCT01632904 · Incyte Corporation
2012-06 – 2016-05 · Polycythemia Vera
What this study did
NCT02087059 · Novartis Pharmaceuticals
2014-04 – 2015-04 · Primary Myelofibrosis (MF)
What this study did
Other / comorbidity
NCT06401356 · Novartis Pharmaceuticals
2024-08-13 – 2029-12-31 · Hematologic Malignancy, Solid Tumor, Advanced Malignancies
What this study did
NCT07588945 · Institute of Hematology & Blood Diseases Hospital, China
2027-01-01 – 2028-06-01 · Transplant-Related Disorder
What this study did
NCT05137496 · Beijing Friendship Hospital
2022-06-01 – 2024-06-01 · Macrophage Activation Syndrome
What this study did
NCT05663827 · Yi-Lun Wang
2019-01-01 – 2022-11-30 · Steroid Refractory GVHD
What this study did
NCT04424056 · Assistance Publique Hopitaux De Marseille
2020-09-01 – 2022-11-01 · Covid19
What this study did
NCT02913261 · Novartis Pharmaceuticals
2017-03-10 – 2021-04-23 · Corticosteroid Refractory Acute Graft vs Host Disease
What this study did
NCT04377620 · Incyte Corporation
2020-05-24 – 2021-02-26 · COVID-19
What this study did
NCT04120090 · Beijing Friendship Hospital
2019-07-01 – 2020-07-01 · Hemophagocytic Lymphohistiocytosis
What this study did
NCT02117479 · Incyte Corporation
2014-03 – 2016-12 · Pancreatic Cancer
What this study did
NCT02119663 · Incyte Corporation
2014-06 – 2016-10 · Pancreatic Cancer
What this study did
Phase 2/3 (7)
Graft-versus-Host Disease
NCT07297914 · Bambino Gesù Hospital and Research Institute
2026-01-07 – 2032-12-01 · Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant, Graft -Versus-host-disease
What this study did
NCT07366801 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2025-09-03 – 2028-02-03 · Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk, Acute Lymphoblastic Leukemia, Relapse
What this study did
Other / comorbidity
NCT03117751 · St. Jude Children's Research Hospital
2017-03-29 – 2028-09-30 · Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
What this study did
NCT06951971 · The First Affiliated Hospital of Soochow University
2025-06-01 – 2028-06-01 · Hemophagocytic Lymphohistiocytosis (HLH)
What this study did
NCT04348071 · University of Colorado, Denver
2021-07 – 2021-10 · COVID-19
What this study did
NCT02962388 · French Innovative Leukemia Organisation
2017-01-03 – 2021-06-28 · Essential Thrombocythemia
What this study did
NCT04477993 · Vanderson Geraldo Rocha
2020-08-14 – 2021-03-29 · Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV2
What this study did
Phase 2 (138)
Chronic Graft-versus-Host Disease
NCT07643025 · Dennis Kim
2026-11 – 2030-11 · cGVHD
What this study did
NCT06756061 · Byung-Sik Cho
2025-01-15 – 2029-08-31 · GVHD - Graft-Versus-Host Disease, Neoplasms, Haematopoietic Stem Cell Transplantation
What this study did
NCT06388564 · Incyte Corporation
2024-10-11 – 2029-03-30 · Chronic Graft-versus-host-disease
What this study did
NCT06660355 · H. Lee Moffitt Cancer Center and Research Institute
2024-12-23 – 2028-12 · Chronic Graft-versus-host Disease (cGVHD)
What this study did
NCT03616184 · University of Nebraska
2018-09-05 – 2023-06-12 · Graft-versus-host-disease (GVHD)
What this study did
Graft-versus-Host Disease
NCT07359859 · Memorial Sloan Kettering Cancer Center
2026-01-20 – 2029-01 · Hematologic Malignancies
What this study did
NCT05622318 · Medical College of Wisconsin
2023-08-29 – 2028-08-06 · Graft-versus-host Disease
What this study did
NCT06859424 · Center for International Blood and Marrow Transplant Research
2025-07-25 – 2028-06 · AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
What this study did
NCT06936566 · John Levine
2025-05-14 – 2028-04-14 · Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
What this study did
NCT07509749 · Daihong Liu
2025-06-30 – 2027-12-30 · GVHD, Acute, Stem Cell Transplant Complications
What this study did
NCT07356245 · Ohio State University Comprehensive Cancer Center
2026-02-12 – 2027-10-31 · T-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-Cell, Peripheral T Cell Lymphoma, T-cell Prolymphocytic Leukemia, Cutaneous T Cell Lymphoma, Adult T-cell Leukemia/Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
What this study did
NCT07340723 · Daihong Liu
2025-06-01 – 2027-06-01 · GVHD,Acute, Stem Cell Transplant Complications
What this study did
NCT07249346 · Hannah Choe, MD
2026-01-14 – 2027-06-01 · Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia
What this study did
NCT04669210 · St. Petersburg State Pavlov Medical University
2020-11-03 – 2025-03-28 · Graft-versus-host-disease, Stem Cell Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
What this study did
NCT05600855 · Institute of Hematology & Blood Diseases Hospital, China
2023-01-15 – 2024-12-01 · Transplant-Related Disorder
What this study did
NCT05599256 · Institute of Hematology & Blood Diseases Hospital, China
2023-02-09 – 2024-12-01 · Transplant-Related Disorder
What this study did
Myelofibrosis
NCT07228624 · Fred Hutchinson Cancer Center
2026-02-04 – 2030-09-01 · Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
What this study did
NCT04384692 · Fred Hutchinson Cancer Center
2020-12-18 – 2030-04-23 · Primary Myelofibrosis, Secondary Myelofibrosis
What this study did
NCT05037760 · Takeda
2021-12-16 – 2030-02-28 · Myelofibrosis
What this study did
NCT06345495 · M.D. Anderson Cancer Center
2024-10-01 – 2029-01-01 · Splenomegaly, Myelofibrosis
What this study did
NCT05980806 · Karyopharm Therapeutics Inc
2024-04-22 – 2028-10 · Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
What this study did
NCT03069326 · Memorial Sloan Kettering Cancer Center
2017-02-27 – 2027-02 · Myelofibrosis
What this study did
NCT06397313 · Ryvu Therapeutics SA
2024-09-19 – 2026-06-30 · Myelofibrosis
What this study did
NCT02251821 · Fred Hutchinson Cancer Center
2014-10-20 – 2026-01-22 · Primary Myelofibrosis, Secondary Myelofibrosis
What this study did
NCT03427866 · Massachusetts General Hospital
2018-08-28 – 2025-05-19 · Myelofibrosis
What this study did
NCT06619522 · M.D. Anderson Cancer Center
2024-09-11 – 2025-05-09 · Myelofibrosis
What this study did
NCT03222609 · AbbVie
2017-10-31 – 2025-01-29 · Myelofibrosis (MF)
What this study did
NCT02784496 · M.D. Anderson Cancer Center
2016-09-29 – 2024-01-23 · Myelofibrosis
What this study did
NCT04218071 · Actuate Therapeutics Inc.
2020-08-20 – 2024-01-18 · Myelofibrosis
What this study did
NCT04281498 · John Mascarenhas
2021-01-14 – 2023-05-30 · Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation
What this study did
NCT04543279 · Washington University School of Medicine
2021-05-03 – 2022-07-30 · Myelofibrosis, Thrombocytopenia
What this study did
NCT01712308 · M.D. Anderson Cancer Center
2013-02-21 – 2022-05-24 · Anemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis
What this study did
NCT02718300 · Incyte Corporation
2017-02-08 – 2022-04-29 · MPN (Myeloproliferative Neoplasms)
What this study did
NCT03144687 · Incyte Corporation
2018-01-26 – 2021-06-01 · MPN (Myeloproliferative Neoplasms)
What this study did
NCT01795677 · French Innovative Leukemia Organisation
2012-12 – 2019-03 · Myelofibrosis
What this study did
NCT01375140 · M.D. Anderson Cancer Center
2011-09-22 – 2018-09-05 · Myeloproliferative Diseases
What this study did
NCT02267278 · M.D. Anderson Cancer Center
2015-01-12 – 2018-06-01 · Myeloproliferative Diseases
What this study did
NCT01732445 · Mayo Clinic
2013-04 – 2017-08-10 · Anemia, Primary Myelofibrosis, Secondary Myelofibrosis
What this study did
NCT01523171 · Bristol-Myers Squibb
2012-04-30 – 2014-04-30 · Hematopoietic Neoplasm
What this study did
NCT01340651 · Incyte Corporation
2011-03 – 2012-07 · Myelofibrosis
What this study did
Polycythemia Vera
NCT04644211 · Massachusetts General Hospital
2022-03-21 – 2034-07 · Essential Thrombocythemia, Polycythemia Vera
What this study did
NCT02577926 · RWTH Aachen University
2015-10 – 2028-12 · Polycythemia Vera (PV), Essential Thrombocythemia (ET)
What this study did
NCT05870475 · Institute of Hematology & Blood Diseases Hospital, China
2023-06-30 – 2028-05-31 · Polycythemia Vera
What this study did
NCT04282187 · University of Washington
2020-03-24 – 2027-11-11 · Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Not Otherwise Specified, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
What this study did
NCT01787487 · M.D. Anderson Cancer Center
2013-03-13 – 2026-01-20 · Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
What this study did
NCT01981850 · Hoffmann-La Roche
2013-10-01 – 2020-07-10 · Primary Myelofibrosis, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis
What this study did
Phase 1/2 (62)
Graft-versus-Host Disease
NCT05123040 · Masonic Cancer Center, University of Minnesota
2023-06-05 – 2026-02-27 · Acute-graft-versus-host Disease
What this study did
NCT03491215 · Novartis Pharmaceuticals
2019-02-21 – 2023-02-02 · Acute Graft Versus Host Disease
What this study did
Myelofibrosis
NCT07128381 · M.D. Anderson Cancer Center
2026-01-02 – 2033-07-31 · Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML)
What this study did
NCT04176198 · Sumitomo Pharma America, Inc.
2019-12-16 – 2030-04-30 · Myelofibrosis
What this study did
NCT04817007 · Bristol-Myers Squibb
2021-03-22 – 2028-08-31 · Myelofibrosis
What this study did
NCT06909136 · Suzhou Junjing BioSciences Co., Ltd.
2025-07-28 – 2028-05-15 · Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly
What this study did
NCT06773195 · Memorial Sloan Kettering Cancer Center
2025-01-07 – 2028-01 · Myelofibrosis
What this study did
NCT05280509 · Telios Pharma, Inc.
2022-06-09 – 2027-04 · Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
What this study did
NCT02158858 · Constellation Pharmaceuticals
2014-07-16 – 2025-01-09 · Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic Syndrome (MDS), Preleukemia, Primary Myelofibrosis, Myeloproliferative Disorders, Bone Marrow Disease, Hematological Disease, Precancerous Conditions, Neoplasms, Leukemia, Neoplasms by Histologic Type, Essential Thrombocytosis
What this study did
NCT04097821 · Novartis Pharmaceuticals
2019-09-26 – 2024-08-28 · Myelofibrosis
What this study did
NCT01644110 · University of Ulm
2013-08 – 2024-04-27 · Primary Myelofibrosis, Secondary Myelofibrosis, PMF, SMF, Post-PV MF, Post-ET MF
What this study did
NCT04354727 · Ascentage Pharma Group Inc.
2020-12-15 – 2023-06-15 · Myelofibrosis
What this study did
NCT02742324 · French Innovative Leukemia Organisation
2016-03 – 2021-12-31 · Myelofibrosis
What this study did
NCT02806375 · St. Petersburg State Pavlov Medical University
2016-01 – 2019-04 · Primary Myelofibrosis, Myeloproliferative Disorders
What this study did
NCT01693601 · John Mascarenhas
2013-01 – 2018-05-18 · Myelofibrosis
What this study did
Polycythemia Vera
NCT06327100 · M.D. Anderson Cancer Center
2024-08-01 – 2031-05-01 · Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis
What this study did
NCT07734077 · John Mascarenhas
2026-12-01 – 2028-12-01 · Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
What this study did
NCT04455841 · Incyte Corporation
2021-03-19 – 2026-09-08 · Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
What this study did
NCT03878199 · Ohio State University Comprehensive Cancer Center
2019-02-20 – 2025-02-27 · Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera, Secondary Acute Myeloid Leukemia
What this study did
NCT01787552 · Novartis Pharmaceuticals
2013-05-08 – 2018-04-10 · Primary Myelofibrosis, Thrombocytosis, Essential Thrombocythemia, Polycythemia Vera, Myeloproliferative Disorders, Bone Marrow Diseases, Hematologic Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, Hemorrhagic Disorders
What this study did
NCT00509899 · Incyte Corporation
2007-06 – 2017-02 · Myelofibrosis, Polycythemia Vera, Thrombocytosis
What this study did
Other / comorbidity
NCT05998408 · National Heart, Lung, and Blood Institute (NHLBI)
2024-02-20 – 2032-06-03 · Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS
What this study did
NCT05745714 · Princess Maxima Center for Pediatric Oncology
2025-10-01 – 2032-02-02 · Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
What this study did
NCT07311746 · M.D. Anderson Cancer Center
2026-04-28 – 2031-01-31 · T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia
What this study did
NCT06616155 · University of Michigan Rogel Cancer Center
2026-06 – 2030-06 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
What this study did
NCT07219576 · University of California, San Diego
2026-01-08 – 2029-12 · Non Small Cell Lung Carcinoma, Renal Cell Carcinoma
What this study did
NCT07252050 · Arkansas Children's Hospital Research Institute
2026-06-08 – 2029-11-19 · Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant, Haploidentical Stem Cell Transplantation, Graft Failure
What this study did
NCT04856137 · National Health Research Institutes, Taiwan
2021-05-01 – 2028-12-31 · Refractory Diffuse Large B-cell Lymphoma
What this study did
NCT07796620 · Peking University People's Hospital
2026-10-01 – 2028-09-30 · Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia (SAA)
What this study did
NCT04061421 · Michael Savona
2021-11-24 – 2027-12 · MDS/MPN
What this study did
NCT03681561 · Veronika Bachanova
2018-09-13 – 2027-07 · Hodgkin Lymphoma
What this study did
NCT06607367 · Melbourne Health
2024-10-30 – 2026-10-30 · Poor Graft Function, Aplastic Anemia Idiopathic
What this study did
NCT05909943 · Tianjin Medical University General Hospital
2024-06-01 – 2026-08-01 · Neuromyelitis Optica Spectrum Disorder Relapse
What this study did
NCT04551131 · St. Jude Children's Research Hospital
2021-07-13 – 2026-08 · Hemophagocytic Lymphohistiocytosis
What this study did
NCT04582604 · Chinese PLA General Hospital
2020-09-01 – 2025-09-30 · Peripheral Blood Stem Cell Transplantation
What this study did
NCT05075681 · Chinese PLA General Hospital
2021-11-01 – 2025-06-01 · Peripheral Blood Stem Cell Transplantation
What this study did
NCT05998395 · National Heart, Lung, and Blood Institute (NHLBI)
2023-09-28 – 2025-02-28 · Kohlmeier Degos Disease With Neurologic Involvement, Kohlmeier-Degos Disease
What this study did
NCT04269850 · St. Petersburg State Pavlov Medical University
2019-09-01 – 2024-11-27 · Intestinal GVHD
What this study did
NCT03558607 · Seoul National University Hospital
2018-05-17 – 2024-08-31 · Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder
What this study did
NCT02713386 · NRG Oncology
2016-11-14 – 2024-05-22 · Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IIIA Ovarian Cancer 2014, FIGO Stage IIIA1 Ovarian Cancer, FIGO Stage IIIA2 Ovarian Cancer, FIGO Stage IIIB Ovarian Cancer 2014, FIGO Stage IIIC Ovarian Cancer 2014, FIGO Stage IVA Ovarian Cancer 2014, FIGO Stage IVB Ovarian Cancer 2014, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
What this study did
NCT03773107 · Wake Forest University Health Sciences
2019-01-03 – 2024-02-21 · Multiple Myeloma
What this study did
NCT04581954 · Imperial College London
2020-10-02 – 2023-09-02 · Coronavirus, Covid19, Pneumonia
What this study did
NCT02152956 · MacroGenics
2014-06-09 – 2022-07-05 · AML
What this study did
NCT01776723 · H. Lee Moffitt Cancer Center and Research Institute
2013-02-20 – 2022-05-10 · Myelomonocytic Leukemia
What this study did
NCT03795909 · Capital Research Institute of Pediatrics
2017-03-01 – 2022-03-01 · Hemophagocytic Lymphohistiocytosis
What this study did
NCT01712659 · National Cancer Institute (NCI)
2012-10-26 – 2022-01-18 · T Cell Leukemia, Adult, Leukemia, Adult T-Cell, T Cell Leukemia, HTLV I Associated
What this study did
NCT02973711 · University of Michigan Rogel Cancer Center
2018-01 – 2021-08 · Leukemia, Chronic Myeloid
What this study did
NCT04334044 · Grupo Cooperativo de Hemopatías Malignas
2020-09-01 – 2021-04-30 · COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2
What this study did
NCT03613428 · Sichuan University
2018-12-01 – 2021-03-30 · Acute T Cell Leukemia
What this study did
Phase 1 (76)
Chronic Graft-versus-Host Disease
NCT06233110 · Stefanie Sarantopoulos, MD, PhD.
2025-10-29 – 2029-07-01 · Chronic Graft Versus Host Disease
What this study did
NCT07025538 · City of Hope Medical Center
2026-04-29 – 2028-06-22 · Hematopoietic and Lymphatic System Neoplasm
What this study did
NCT06695507 · Children's Hospital Medical Center, Cincinnati
2025-02-19 – 2025-09-18 · Chronic Graft Versus Host Disease
What this study did
NCT05121142 · Children's Hospital Medical Center, Cincinnati
2021-10-27 – 2023-05-13 · Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Solid Organ Transplant
What this study did
Graft-versus-Host Disease
NCT04744116 · M.D. Anderson Cancer Center
2021-02-17 – 2032-03-31 · Hematopoietic and Lymphoid Cell Neoplasm, Steroid Refractory Graft Versus Host Disease
What this study did
NCT07913672 · Memorial Sloan Kettering Cancer Center
2026-10-27 – 2028-10-27 · Transplant Failure or Rejection of Bone Marrow (Graft vs Host Disease, GVHD)
What this study did
NCT07576010 · Daihong Liu
2025-01-17 – 2027-12-30 · Acute Graft-versus-host Disease
What this study did
NCT06008808 · Washington University School of Medicine
2024-05-07 – 2027-11-27 · Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
What this study did
NCT02528877 · City of Hope Medical Center
2015-11 – 2016-09 · Acute Myeloid Leukemia in Remission, Primary Myelofibrosis, Primary Myelofibrosis, Prefibrotic Stage, Secondary Acute Myeloid Leukemia, Secondary Myelofibrosis
What this study did
Myelofibrosis
NCT07521046 · University of Utah
2026-08-21 – 2030-08 · Myelofibrosis
What this study did
NCT04328844 · iOnctura
2020-02-25 – 2028-03 · Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis, Uveal Melanoma
What this study did
NCT05423691 · Cellenkos, Inc.
2022-12-27 – 2027-12-30 · Myelofibrosis
What this study did
NCT07802405 · Henan Cancer Hospital
2023-11-21 – 2027-11-21 · MF With Splenomegaly
What this study did
NCT06388759 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2022-08-01 – 2025-08-12 · Myelofibrosis
What this study did
NCT02917096 · City of Hope Medical Center
2016-11-13 – 2023-08-31 · Primary Myelofibrosis, Secondary Myelofibrosis
What this study did
NCT03386214 · Washington University School of Medicine
2018-04-23 – 2021-10-04 · Myelofibroses
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT02370706 · Novartis Pharmaceuticals
2015-05-21 – 2020-11-09 · Myelofibrosis
What this study did
NCT01730248 · Novartis Pharmaceuticals
2012-12-18 – 2017-09-28 · Myelofibrosis
What this study did
Polycythemia Vera
NCT07340138 · Novartis Pharmaceuticals
2026-04-15 – 2030-09-21 · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
What this study did
NCT04279847 · Incyte Corporation
2021-02-23 – 2027-04-30 · Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), ET (Essential Thrombocythemia)
What this study did
NCT05714072 · Memorial Sloan Kettering Cancer Center
2023-01-25 – 2027-01 · Myelofibrosis Due to and Following Polycythemia Vera
What this study did
NCT02493530 · Vanderbilt-Ingram Cancer Center
2015-07 – 2024-05 · Myelofibrosis, Polycythemia Vera
What this study did
NCT03935555 · Samus Therapeutics, Inc.
2019-08-12 – 2022-11-04 · Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
What this study did
NCT01433445 · Novartis Pharmaceuticals
2011-11-01 – 2020-06-22 · Idiopathic Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia-Vera Myelofibrosis
What this study did
NCT03373877 · Samus Therapeutics, Inc.
2018-05-24 – 2020-03-10 · Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
What this study did
Other / comorbidity
NCT06768476 · University of Pennsylvania
2025-02-28 – 2045-03 · Relapsed AML, Refractory AML
What this study did
NCT03017820 · Mayo Clinic
2017-04-04 – 2032-04-01 · B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Plasma Cell Myeloma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Plasma Cell Myeloma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
What this study did
NCT06508463 · Mayo Clinic
2024-01-05 – 2032-04-01 · Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Relapsed Anaplastic Large Cell Lymphoma, Relapsed Mycosis Fungoides
What this study did
NCT07849231 · Damora Therapeutics
2026-09 – 2030-06 · Myeloproliferative Neoplasms (MPNs)
What this study did
NCT07464951 · Stephan Grupp MD PhD
2026-05-14 – 2030-05-14 · Acute Myeloid Leukemia (AML)
What this study did
NCT07566897 · Philogen S.p.A.
2026-05-01 – 2030-05 · Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Metastatic Colorectal Carcinoma (mCRC)
What this study did
NCT06291987 · University of Chicago
2024-09-19 – 2029-05 · Myeloproliferative Neoplasms
What this study did
NCT07424222 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2026-07-15 – 2029-02-01 · Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
What this study did
NCT06209606 · Oncotherapeutics
2022-12-08 – 2029-02 · Multiple Myeloma
What this study did
NCT07548983 · OHSU Knight Cancer Institute
2026-04-21 – 2028-12-29 · Acute Myeloid Leukemia
What this study did
NCT05098210 · Fred Hutchinson Cancer Center
2022-06-09 – 2028-11-01 · Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma, Metastatic Acral Melanoma, Metastatic Conjunctival Melanoma, Metastatic Cutaneous Melanoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Mucosal Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma, Recurrent HER2-Negative Breast Carcinoma, Recurrent Hormone Receptor-Positive Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Mucosal Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Mucosal Melanoma
What this study did
NCT06034002 · Incyte Corporation
2023-12-04 – 2028-10-29 · Myeloproliferative Neoplasms
What this study did
NCT06150157 · Janssen Research & Development, LLC
2023-12-20 – 2028-06-14 · Neoplasms
What this study did
NCT05088356 · Stanford University
2021-09-07 – 2028-05 · Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
What this study did
NCT05936359 · Incyte Corporation
2023-09-25 – 2028-02-29 · Myeloproliferative Neoplasms
What this study did
NCT03120624 · Mayo Clinic
2017-09-15 – 2028-01-01 · Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinosarcoma, Stage IV Uterine Corpus Cancer AJCC v7
What this study did
NCT03874052 · Jennifer Saultz
2019-08-16 – 2027-12-31 · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Secondary Acute Myeloid Leukemia
What this study did
NCT07278856 · City of Hope Medical Center
2025-12-16 – 2027-12-10 · Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type, Follicular Helper T-Cell Lymphoma, Not Otherwise Specified, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
What this study did
Phase 4 (13)
Graft-versus-Host Disease
CINC424A2X01B Rollover Protocolactive not recruiting
NCT02386800 · Novartis Pharmaceuticals
2015-03-05 – 2032-04-05 · Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia, Thalassemia
What this study did
NCT06462469 · Novartis Pharmaceuticals
2024-07-04 – 2027-07-08 · Steroid-refractory Acute Graft Versus Host Disease
What this study did
Myelofibrosis
NCT07498205 · SWOG Cancer Research Network
2026-11 – 2031-08-08 · Myelofibrosis, Myelofibrosis (MF)
What this study did
NCT05447260 · Qilu Hospital of Shandong University
2022-06-10 – 2023-12-10 · Myelofibrosis
What this study did
NCT01558739 · Novartis Pharmaceuticals
2012-05 – 2014-01 · Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF), Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
What this study did
Other / comorbidity
NCT06824103 · Novartis Pharmaceuticals
2025-09-09 – 2031-05-23 · Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease
What this study did
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT07101588 · Chinese PLA General Hospital
2025-01-01 – 2028-12-30 · Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
What this study did
NCT06364319 · Peking University People's Hospital
2026-07-15 – 2028-06-30 · cGVHD
What this study did
NCT05491304 · The Children's Hospital of Zhejiang University School of Medicine
2022-09-01 – 2025-12-31 · Hemophagocytic Lymphohistiocytoses, Cytokine Storm
What this study did
NCT04999878 · Zhengzhou University
2021-05-30 – 2024-06-30 · Hemophagocytic Syndrome, T/NK-Cell Lymphoma
What this study did
NCT05021276 · The First Affiliated Hospital of Soochow University
2020-12-15 – 2022-12-15 · Safety and Efficacy
What this study did
NCT04446806 · The First Affiliated Hospital of Soochow University
2019-06-01 – 2021-05-31 · Safety and Efficacy
What this study did
Early phase / not applicable (8)
Graft-versus-Host Disease
Myelofibrosis
NCT02469974 · Marina Kremyanskaya
2015-05 – 2016-08 · Myelofibrosis, MF
What this study did
Other / comorbidity
NCT07131059 · Institute of Hematology & Blood Diseases Hospital, China
2024-05-11 – 2028-10-30 · AML, Adult
What this study did
NCT07184853 · First Affiliated Hospital of Zhejiang University
2025-09-25 – 2028-09-25 · Graft vs Host Disease
What this study did
NCT05899725 · Peking Union Medical College Hospital
2023-04-14 – 2026-06-30 · Severe Checkpoint Inhibitor Pneumonitis
What this study did
NCT04526223 · xuna
2017-04-20 – 2022-12-31 · Time of Hematopoietic Reconstruction
What this study did
NCT04331665 · University Health Network, Toronto
2020-05-21 – 2021-03-24 · COVID-19, Pneumonia
What this study did
NCT03274778 · Oncology Institute of Southern Switzerland
2017-09-01 – 2020-03-24 · Prostate Cancer
What this study did
Used as active comparator (12)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Graft-versus-Host Disease
NCT04934670 · Xenikos
2022-06-16 – 2023-01-19 · Steroid-Refractory Acute Graft Versus Host Disease
What this study did
Myelofibrosis
NCT07317700 · Chengdu Zenitar Biomedical Technology Co., Ltd
2026-02-13 – 2028-03-30 · MF
What this study did
Polycythemia Vera
NCT01969838 · Sierra Oncology LLC - a GSK company
2013-12-06 – 2019-05-02 · Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
What this study did
Other / comorbidity
Phase 2/3 (1)
Polycythemia Vera
NCT07722611 · Merck Sharp & Dohme LLC
2026-10-29 – 2032-11-30 · Polycythemia Vera
What this study did
Phase 2 (5)
Graft-versus-Host Disease
NCT05132166 · University Health Network, Toronto
2021-12-22 – 2026-04-26 · Graft Vs Host Disease
What this study did
Myelofibrosis
NCT06457425 · Chengdu Zenitar Biomedical Technology Co., Ltd
2024-05-06 – 2027-05-12 · MF,PMF,PPV-MF,PET-MF
What this study did
NCT03333187 · Universitätsklinikum Hamburg-Eppendorf
2016-12-21 – 2025-10-07 · Bone Marrow Fibrosis
What this study did
Polycythemia Vera
NCT03669965 · Kartos Therapeutics, Inc.
2019-01-15 – 2022-10 · Polycythemia Vera
What this study did
Other / comorbidity
NCT06477549 · St. Petersburg State Pavlov Medical University
2024-06-21 – 2029-06 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma, Myeloproliferative Neoplasm, Myelodysplastic Syndromes
What this study did
Phase 1 (1)
Other / comorbidity
NCT02960945 · Concert Pharmaceuticals
2016-11 – 2017-03 · Healthy
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07794514 · First Affiliated Hospital of Zhejiang University
2026-10-01 – 2030-12-31 · Hematopoietic Stem Cell Transplantation (HSCT), cGVHD, Hepatic cGVHD, Belumosudil, Ruxolitinib
What this study did
Appears in other studies (9)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (7)
Myelofibrosis
NCT06479135 · Kartos Therapeutics, Inc.
2024-06-03 – 2028-12-31 · Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF
What this study did
NCT04562389 · Karyopharm Therapeutics Inc
2021-03-11 – 2028-03 · Myelofibrosis
What this study did
Polycythemia Vera
NCT07357727 · Novartis Pharmaceuticals
2026-05-27 – 2030-12-27 · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
What this study did
NCT04603495 · Novartis Pharmaceuticals
2021-04-09 – 2027-06-30 · Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
What this study did
NCT04551066 · Incyte Corporation
2021-05-24 – 2024-11-25 · Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
What this study did
NCT04551053 · Incyte Corporation
2021-05-26 – 2024-08-21 · Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
What this study did
Phase 2 (1)
Other / comorbidity
NCT06664970 · Peking Union Medical College Hospital
2024-11-06 – 2026-09-30 · MDS
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07909668 · Kafrelsheikh University
2026-07-01 – 2027-01-01 · Vitiligo, Nonsegmental Vitiligo
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Chronic Graft-versus-Host Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ruxolitinib (Jakafi): this drugApprovedSmall moleculeJAK1/2Partial signal
NCT03112603: Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit (Cycle 7 Day 1 (each cycle was comprised of 4 weeks)): Ruxolitinib 49.7 percentage of participants (95% CI 41.8 to 57.6) | Best Available Therapy 25.6 percentage of participants (95% CI 19.1 to 33)
AxatilimabApprovedMonoclonal antibodyCSF-1RWeak signalFeatured results are non-efficacy only in this race
Baricitinib (Olumiant)
Approved(overall)
Small moleculeJAK, JAK1/2
Reliable signal(overall)
No reviewed efficacy summary in this indication
BelumosudilApprovedSmall moleculeRho-associated kinase (ROCK, pan)Weak signal
NCT03640481: Overall Response Rate (ORR) (From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 40.5 months for adult arms and 27.6 months for adolescent arms)): Adult Arm A: Belumosudil 200 mg QD 74 Percentage of participants | Adult Arm B: Belumosudil 200 mg BID 76 Percentage of participants | Adolescent Arm A: Belumosudil 200 mg QD 50 Percentage of participants | Adolescent Arm B: Belumosudil 200 mg BID 100 Percentage of participants
IbrutinibApprovedSmall moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
Ruxolitinib (Opzelura)
Approved(overall)
Small moleculeJAK1/2
Reliable signal(overall)
No reviewed efficacy summary in this indication
Pumecitinib
Phase 3(overall)
Small moleculeJAK1/2
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(105 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ruxolitinib (Jakafi) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
November 2026 (2)
Phase 1/2Hodgkin LymphomaRecruiting
Est. primary completion 2026-11 · NCT03681561 · CT.gov ↗
What to watch
Phase 2Inborn Errors of ImmunityRecruiting
Est. primary completion 2026-11-21 · NCT06199427 · CT.gov ↗
What to watch
December 2026 (3)
Phase 2Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell TransplantationActive not recruiting
Est. primary completion 2026-12 · NCT03286530 · CT.gov ↗
What to watch
Phase 2Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic SyndromeEnrolling by invitation
Est. primary completion 2026-12 · NCT06987058 · CT.gov ↗
What to watch
Phase 1Myeloproliferative NeoplasmActive not recruiting
Est. primary completion 2026-12-31 · NCT04041050 · CT.gov ↗
What to watch
2027 (46)
January 2027 (3)
Phase 1MyelofibrosisActive not recruiting
Est. primary completion 2027-01 · NCT04454658 · CT.gov ↗
What to watch
Phase 1MyelofibrosisRecruiting
Est. primary completion 2027-01 · NCT05714072 · CT.gov ↗
What to watch
Phase 2MyelofibrosisRecruiting
Est. primary completion 2027-01-01 · NCT06345495 · CT.gov ↗
What to watch
February 2027 (2)
Phase 1MyelofibrosisActive not recruiting
Est. primary completion 2027-02 · NCT05371964 · CT.gov ↗
What to watch
Phase 2MyelofibrosisActive not recruiting
Est. primary completion 2027-02 · NCT03069326 · CT.gov ↗
What to watch
April 2027 (4)
Phase 1Multiple Myeloma in Relapse, Multiple Myeloma, RefractoryRecruiting
Est. primary completion 2027-04-01 · NCT06225310 · CT.gov ↗
What to watch
Phase 1MyelofibrosisActive not recruiting
Est. primary completion 2027-04-30 · NCT04279847 · CT.gov ↗
What to watch
Phase 1MyelofibrosisRecruiting
Est. primary completion 2027-04-30 · NCT05423691 · CT.gov ↗
What to watch
Phase 1/2MyelofibrosisRecruiting
Est. primary completion 2027-04-30 · NCT04176198 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2Haemophagocytic LymphohistiocytosisRecruiting
Est. primary completion 2027-05 · NCT05762640 · CT.gov ↗
What to watch
Phase 2Carcinoma, Non-Small-Cell LungActive not recruiting
Est. primary completion 2027-05-31 · NCT06120140 · CT.gov ↗
What to watch
June 2027 (10)
Phase 1Metastatic Triple-Negative Breast Carcinoma, Breast CancerRecruiting
Est. primary completion 2027-06 · NCT06008275 · CT.gov ↗
What to watch
Phase 1Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2027-06 · NCT02494882 · CT.gov ↗
What to watch
Phase 2MyelofibrosisRecruiting
Est. primary completion 2027-06 · NCT05980806 · CT.gov ↗
What to watch
Phase 2Graft-versus-Host DiseaseRecruiting
Est. primary completion 2027-06-01 · NCT07340723 · CT.gov ↗
What to watch
Phase 2Graft-versus-Host DiseaseRecruiting
Est. primary completion 2027-06-01 · NCT06936566 · CT.gov ↗
What to watch
Phase 2Graft-versus-Host DiseaseRecruiting
Est. primary completion 2027-06-01 · NCT07249346 · CT.gov ↗
What to watch
Phase 2Targeted Therapy, IDH1-Mutated Malignancies, MutationsRecruiting
Est. primary completion 2027-06-01 · NCT07032727 · CT.gov ↗
What to watch
Phase 2/3Hemophagocytic Lymphohistiocytosis (HLH)Not yet recruiting
Est. primary completion 2027-06-01 · NCT06951971 · CT.gov ↗
What to watch
Phase 2/3Graft-versus-Host DiseaseRecruiting
Est. primary completion 2027-06-01 · NCT07366801 · CT.gov ↗
What to watch
Phase 1NeoplasmsRecruiting
Est. primary completion 2027-06-14 · NCT06150157 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Polycythemia VeraRecruiting
Est. primary completion 2027-07 · NCT04644211 · CT.gov ↗
What to watch
Phase 2T-Cell Large Granular Lymphocyte LeukemiaRecruiting
Est. primary completion 2027-07-31 · NCT05592015 · CT.gov ↗
What to watch
August 2027 (2)
Phase 1T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte LeukemiaActive not recruiting
Est. primary completion 2027-08 · NCT05010005 · CT.gov ↗
What to watch
Phase 1/2MDS/MPNRecruiting
Est. primary completion 2027-08 · NCT04061421 · CT.gov ↗
What to watch
September 2027 (4)
Phase 1Graft-versus-Host DiseaseRecruiting
Est. primary completion 2027-09-08 · NCT06008808 · CT.gov ↗
What to watch
Early phase / not applicableGraft vs Host DiseaseRecruiting
Est. primary completion 2027-09-25 · NCT07184853 · CT.gov ↗
What to watch
Phase 1/2Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia (SAA)Not yet recruiting
Est. primary completion 2027-09-30 · NCT07796620 · CT.gov ↗
What to watch
Phase 2Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT02955940 · CT.gov ↗
What to watch
October 2027 (2)
Phase 1/2MyelofibrosisActive not recruiting
Est. primary completion 2027-10-31 · NCT06909136 · CT.gov ↗
What to watch
Phase 2Graft-versus-Host DiseaseRecruiting
Est. primary completion 2027-10-31 · NCT07356245 · CT.gov ↗
What to watch
November 2027 (4)
Phase 2LymphomaRecruiting
Est. primary completion 2027-11 · NCT02974647 · CT.gov ↗
What to watch
Phase 1Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma …Recruiting
Est. primary completion 2027-11-01 · NCT05098210 · CT.gov ↗
What to watch
Phase 2Graft-versus-Host DiseaseRecruiting
Est. primary completion 2027-11-01 · NCT06756061 · CT.gov ↗
What to watch
Phase 2MyelofibrosisRecruiting
Est. primary completion 2027-11-11 · NCT04282187 · CT.gov ↗
What to watch
December 2027 (11)
Phase 1/2Non Small Cell Lung Carcinoma, Renal Cell CarcinomaRecruiting
Est. primary completion 2027-12 · NCT07219576 · CT.gov ↗
What to watch
Phase 2Polycythemia VeraActive not recruiting
Est. primary completion 2027-12 · NCT02577926 · CT.gov ↗
What to watch
Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia AreataRecruiting
Est. primary completion 2027-12-01 · NCT05398809 · CT.gov ↗
What to watch
Phase 1Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma …Recruiting
Est. primary completion 2027-12-10 · NCT07278856 · CT.gov ↗
What to watch
Phase 2Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, Myelodysplastic Syndromes (MDS), Myeloprolipherative Neoplsm …Active not recruiting
Est. primary completion 2027-12-10 · NCT07238712 · CT.gov ↗
What to watch
Phase 1Graft-versus-Host DiseaseActive not recruiting
Est. primary completion 2027-12-30 · NCT07576010 · CT.gov ↗
What to watch
Phase 2Graft-versus-Host DiseaseRecruiting
Est. primary completion 2027-12-30 · NCT07509749 · CT.gov ↗
What to watch
Phase 1Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia …Recruiting
Est. primary completion 2027-12-31 · NCT03874052 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT07548983 · CT.gov ↗
What to watch
Phase 3Transplant-Related DisorderNot yet recruiting
Est. primary completion 2027-12-31 · NCT07588945 · CT.gov ↗
What to watch
Phase 4cGVHDNot yet recruiting
Est. primary completion 2027-12-31 · NCT06364319 · CT.gov ↗
What to watch
2028 (27)
January 2028 (4)
Phase 1/2MyelofibrosisRecruiting
Est. primary completion 2028-01 · NCT06773195 · CT.gov ↗
What to watch
Phase 2Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Hodgkin Disease Recurrent, Gray Zone Lymphoma …Recruiting
Est. primary completion 2028-01 · NCT07283822 · CT.gov ↗
What to watch
Phase 4Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Recruiting
Est. primary completion 2028-01-01 · NCT07101588 · CT.gov ↗
What to watch
Phase 2Graft-versus-Host DiseaseRecruiting
Est. primary completion 2028-01-31 · NCT06973668 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2MyelofibrosisRecruiting
Est. primary completion 2028-02-28 · NCT05037760 · CT.gov ↗
What to watch
Phase 1Myeloproliferative NeoplasmsActive not recruiting
Est. primary completion 2028-02-29 · NCT05936359 · CT.gov ↗
What to watch
March 2028 (1)
Phase 2Polycythemia VeraRecruiting
Est. primary completion 2028-03-31 · NCT05870475 · CT.gov ↗
What to watch
May 2028 (2)
Phase 1Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia …Active not recruiting
Est. primary completion 2028-05 · NCT05088356 · CT.gov ↗
What to watch
Early phase / not applicableAML, AdultRecruiting
Est. primary completion 2028-05-10 · NCT07131059 · CT.gov ↗
What to watch
June 2028 (4)
Phase 1/2Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8Recruiting
Est. primary completion 2028-06 · NCT06616155 · CT.gov ↗
What to watch
Phase 2MyelofibrosisRecruiting
Est. primary completion 2028-06 · NCT06859424 · CT.gov ↗
What to watch
Phase 2Inclusion Body Myositis, SporadicRecruiting
Est. primary completion 2028-06-10 · NCT06536166 · CT.gov ↗
What to watch
Phase 1Graft-versus-Host DiseaseRecruiting
Est. primary completion 2028-06-22 · NCT07025538 · CT.gov ↗
What to watch
July 2028 (3)
Phase 1Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)Recruiting
Est. primary completion 2028-07-01 · NCT07424222 · CT.gov ↗
What to watch
Phase 2Graft-versus-Host DiseaseActive not recruiting
Est. primary completion 2028-07-08 · NCT05622318 · CT.gov ↗
What to watch
Phase 2Castleman's Disease (CD), Idiopathic Multicentric Castleman's DiseaseRecruiting
Est. primary completion 2028-07-31 · NCT07085039 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1/2MyelofibrosisActive not recruiting
Est. primary completion 2028-08-31 · NCT04817007 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2028-09-30 · NCT02131584 · CT.gov ↗
What to watch
October 2028 (3)
Phase 1Graft-versus-Host DiseaseRecruiting
Est. primary completion 2028-10-27 · NCT07913672 · CT.gov ↗
What to watch
Phase 1Myeloproliferative NeoplasmsRecruiting
Est. primary completion 2028-10-29 · NCT06034002 · CT.gov ↗
What to watch
Phase 3Polycythemia VeraRecruiting
Est. primary completion 2028-10-31 · NCT04116502 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1/2Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant …Recruiting
Est. primary completion 2028-11-19 · NCT07252050 · CT.gov ↗
What to watch
December 2028 (5)
Phase 2Graft-versus-Host DiseaseRecruiting
Est. primary completion 2028-12 · NCT06660355 · CT.gov ↗
What to watch
Phase 1/2MyelofibrosisNot yet recruiting
Est. primary completion 2028-12-01 · NCT07734077 · CT.gov ↗
What to watch
Phase 1B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome …Recruiting
Est. primary completion 2028-12-31 · NCT03017820 · CT.gov ↗
What to watch
Phase 1Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified …Recruiting
Est. primary completion 2028-12-31 · NCT06508463 · CT.gov ↗
What to watch
Phase 2Hemophagocytic LymphohistiocytosesRecruiting
Est. primary completion 2028-12-31 · NCT06160791 · CT.gov ↗
What to watch
2029 (14)
January 2029 (3)
Phase 2Graft-versus-Host DiseaseRecruiting
Est. primary completion 2029-01 · NCT07359859 · CT.gov ↗
What to watch
Phase 1Graft-versus-Host DiseaseRecruiting
Est. primary completion 2029-01-01 · NCT06233110 · CT.gov ↗
What to watch
Phase 1/2T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic LeukemiaRecruiting
Est. primary completion 2029-01-31 · NCT07311746 · CT.gov ↗
What to watch
February 2029 (2)
Phase 2BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells …Active not recruiting
Est. primary completion 2029-02 · NCT03801434 · CT.gov ↗
What to watch
Phase 2Carcinoma, Squamous Cell of Head and Neck HNSCCNot yet recruiting
Est. primary completion 2029-02 · NCT07840456 · CT.gov ↗
What to watch
May 2029 (4)
Phase 1Myeloproliferative NeoplasmsRecruiting
Est. primary completion 2029-05 · NCT06291987 · CT.gov ↗
What to watch
Phase 1/2MyelofibrosisRecruiting
Est. primary completion 2029-05-01 · NCT06327100 · CT.gov ↗
What to watch
Phase 4Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host DiseaseRecruiting
Est. primary completion 2029-05-10 · NCT06824103 · CT.gov ↗
What to watch
Phase 1Acute Myeloid Leukemia (AML)Recruiting
Est. primary completion 2029-05-14 · NCT07464951 · CT.gov ↗
What to watch
August 2029 (2)
Phase 1MyelofibrosisRecruiting
Est. primary completion 2029-08 · NCT07521046 · CT.gov ↗
What to watch
Phase 4MyelofibrosisNot yet recruiting
Est. primary completion 2029-08-08 · NCT07498205 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2Graft-versus-Host DiseaseNot yet recruiting
Est. primary completion 2029-11 · NCT07643025 · CT.gov ↗
What to watch
December 2029 (2)
Phase 1Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Metastatic Colorectal Carcinoma (mCRC)Not yet recruiting
Est. primary completion 2029-12 · NCT07566897 · CT.gov ↗
What to watch
Phase 3Hematologic Malignancy, Solid Tumor, Advanced MalignanciesRecruiting
Est. primary completion 2029-12-31 · NCT06401356 · CT.gov ↗
What to watch
2030 (6)
June 2030 (3)
Phase 1Myeloproliferative Neoplasms (MPNs)Recruiting
Est. primary completion 2030-06 · NCT07849231 · CT.gov ↗
What to watch
Phase 2Peripheral Blood Stem Cell TransplantationRecruiting
Est. primary completion 2030-06-01 · NCT05088226 · CT.gov ↗
What to watch
Phase 4Psoriasis, Atopic DermatitisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2MyelofibrosisRecruiting
Est. primary completion 2030-09-01 · NCT07228624 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2Graft-versus-Host DiseaseRecruiting
Est. primary completion 2030-11-22 · NCT06128070 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Glioblastoma, Brain Cancer, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult …Recruiting
Est. primary completion 2030-12 · NCT06991101 · CT.gov ↗
What to watch
2031 (2)
January 2031 (1)
Phase 3Graft-versus-Host DiseaseRecruiting
Est. primary completion 2031-01-17 · NCT06615050 · CT.gov ↗
What to watch
July 2031 (1)
Phase 1/2MyelofibrosisRecruiting
Est. primary completion 2031-07-31 · NCT07128381 · CT.gov ↗
What to watch
2032 (4)
February 2032 (1)
Phase 1/2Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent …Recruiting
Est. primary completion 2032-02-01 · NCT05745714 · CT.gov ↗
What to watch
March 2032 (1)
Phase 1Graft-versus-Host DiseaseRecruiting
Est. primary completion 2032-03-31 · NCT04744116 · CT.gov ↗
What to watch
April 2032 (1)
Phase 4MyelofibrosisActive not recruiting
Est. primary completion 2032-04-05 · NCT02386800 · CT.gov ↗
What to watch
November 2032 (1)
Phase 2/3Graft-versus-Host DiseaseRecruiting
Est. primary completion 2032-11-30 · NCT07297914 · CT.gov ↗
What to watch
2045 (1)
March 2045 (1)
Phase 1Relapsed AML, Refractory AMLActive not recruiting
Est. primary completion 2045-03 · NCT06768476 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 June 2026Topline resultSENTRY Phase 3 topline results were mixed
7 May 2026Topline resultTRuE-AD4 24-week final data for Opzelura cream
1 May 2026ApprovalFDA approves Jakafi XR (ruxolitinib) extended-release tablets
US, FDA · Source ↗